Advanced prostate cancer poses a significant challenge to healthcare professionals and patients alike. Traditional treatment modalities often reveal limited effectiveness in managing the disease's progression. In recent years, consequently, a novel therapeutic agent has emerged as a promising option for patients with advanced prostate cancer: abira